Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 392

1.

Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.

Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, Schrag D, Khozin S, Capra WB, Taylor MD, Abernethy AP.

JCO Clin Cancer Inform. 2019 Aug;3:1-13. doi: 10.1200/CCI.19.00013.

2.

Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.

Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP.

Cancer. 2019 Nov 15;125(22):4019-4032. doi: 10.1002/cncr.32383. Epub 2019 Aug 5.

3.

An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J.

JCO Clin Cancer Inform. 2019 Jul;3:1-15. doi: 10.1200/CCI.18.00155.

4.

A behavioral cancer pain intervention: A randomized noninferiority trial comparing in-person with videoconference delivery.

Kelleher SA, Winger JG, Dorfman CS, Ingle KK, Moskovich AA, Abernethy AP, Keefe FJ, Samsa GP, Kimmick GG, Somers TJ.

Psychooncology. 2019 Aug;28(8):1671-1678. doi: 10.1002/pon.5141. Epub 2019 Jun 19. Erratum in: Psychooncology. 2020 Jan;29(1):237.

PMID:
31162756
5.

Small But Mighty: The Use of Real-World Evidence to Inform Precision Medicine.

Miksad RA, Samant MK, Sarkar S, Abernethy AP.

Clin Pharmacol Ther. 2019 Jul;106(1):87-90. doi: 10.1002/cpt.1466. Epub 2019 May 21. No abstract available.

6.

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O'Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA.

JAMA. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241. Erratum in: JAMA. 2020 Feb 4;323(5):480.

7.

Implementing an Electronic End-of-Life Chemotherapy Utilization Measure.

Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ.

J Oncol Pract. 2019 Apr;15(4):220-223. doi: 10.1200/JOP.18.00408. Epub 2019 Mar 18. No abstract available.

PMID:
30883256
8.

Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM.

J Am Med Inform Assoc. 2019 Apr 1;26(4):276-285. doi: 10.1093/jamia/ocy169.

9.

Pruritus in patients with solid tumors: an overlooked supportive care need.

Vallely JJ, Hudson KE, Locke SC, Wolf SP, Samsa GP, Abernethy AP, LeBlanc TW.

Support Care Cancer. 2019 Oct;27(10):3897-3904. doi: 10.1007/s00520-019-04693-5. Epub 2019 Feb 14.

PMID:
30762144
10.

Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer.

Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP.

J Geriatr Oncol. 2019 Jul;10(4):669-672. doi: 10.1016/j.jgo.2019.01.016. Epub 2019 Feb 2. No abstract available.

PMID:
30718180
11.

Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.

Khozin S, Carson KR, Zhi J, Tucker M, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister P, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP.

Oncologist. 2019 May;24(5):648-656. doi: 10.1634/theoncologist.2018-0307. Epub 2018 Dec 27.

12.

Coding Error Resulting in Change in Secondary Outcome Scores in Trial of Safety and Benefit of Discontinuing Statin Therapy Among Terminally Ill Patients.

Kutner JS, Abernethy AP.

JAMA Intern Med. 2019 Jan 1;179(1):126. doi: 10.1001/jamainternmed.2018.7162. No abstract available.

PMID:
30508023
13.

Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial.

Currow DC, Ekström M, Louw S, Hill J, Fazekas B, Clark K, Davidson PM, McDonald C, Sajkov D, McCaffrey N, Doogue M, Abernethy AP, Agar M.

Eur Respir J. 2019 Jan 17;53(1). pii: 1801270. doi: 10.1183/13993003.01270-2018. Print 2019 Jan.

PMID:
30361250
14.

Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices.

Whitman ED, Liu FX, Cao X, Diede SJ, Haiderali A, Abernethy AP.

Future Oncol. 2019 Feb;15(5):459-471. doi: 10.2217/fon-2018-0620. Epub 2018 Sep 25.

15.

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.

Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP.

JAMA. 2018 Aug 7;320(5):469-477. doi: 10.1001/jama.2018.9824.

16.

Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study.

Schoen MW, Basch E, Hudson LL, Chung AE, Mendoza TR, Mitchell SA, St Germain D, Baumgartner P, Sit L, Rogak LJ, Shouery M, Shalley E, Reeve BB, Fawzy MR, Bhavsar NA, Cleeland C, Schrag D, Dueck AC, Abernethy AP.

JMIR Hum Factors. 2018 Jul 16;5(3):e10070. doi: 10.2196/10070.

17.

Case Studies from the Clinic: Initiating and Implementing Patient-Reported Outcome Measures.

Locklear T, DeBar LL, Willig J, Rundell S, Blackhall L, Zatzick D, Staman K, Bhavsar N, Weinfurt K, Abernethy AP.

EGEMS (Wash DC). 2017 Jun 12;5(1):7. doi: 10.5334/egems.224.

18.

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.

O'Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP.

JAMA Oncol. 2018 Aug 1;4(8):e180798. doi: 10.1001/jamaoncol.2018.0798. Epub 2018 Aug 9.

19.

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint.

Curtis MD, Griffith SD, Tucker M, Taylor MD, Capra WB, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP.

Health Serv Res. 2018 Dec;53(6):4460-4476. doi: 10.1111/1475-6773.12872. Epub 2018 May 14.

20.

Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study.

Agarwala V, Khozin S, Singal G, O'Connell C, Kuk D, Li G, Gossai A, Miller V, Abernethy AP.

Health Aff (Millwood). 2018 May;37(5):765-772. doi: 10.1377/hlthaff.2017.1579. Review.

PMID:
29733723

Supplemental Content

Loading ...
Support Center